Asimov Center for Breakthrough Medicines Massachusetts California

Asimov and Center for Breakthrough Medicines Form Strategic Partnership for Viral Vector Production

CBM to license Asimov's HEK293 viral vector production platform for use in preclinical and clinical manufacturingHEK293 cell line is GMP-banked and qualified, ready for immediate usePartnership aligns with Asimov's mission to advance the design and manufacture of cell and gene therapiesView original content:https://www.prnewswire.co.uk/news-releases/asimov-and-center-for-breakthrough-medicines-form-strategic-partnership-for-viral-vector-production-301724770.html